Fibromyalgia Treatment Guidelines

Introduction to Fibromyalgia Management

The American College of Physicians and other guideline societies strongly recommend duloxetine at 60 mg daily as first-line pharmacological therapy for fibromyalgia, while gabapentin has insufficient evidence and should not be routinely used 1, 2, 3, 4

The Centers for Disease Control and Prevention guideline explicitly states that evidence for gabapentin in fibromyalgia is insufficient for conditions other than diabetic neuropathy and postherpetic neuralgia, and the FDA has not approved it for fibromyalgia 1, 2, 3
Duloxetine 60 mg provides superior pain relief compared to higher doses, with the higher dose associated with more adverse events and premature discontinuations, according to the American Academy of Pain Medicine 4, 5

The American College of Sports Medicine recommends beginning with patient education about central sensitization and initiating a graduated aerobic exercise program, such as 10-15 minutes of walking, swimming, or cycling 2-3 times weekly, gradually increasing intensity, as part of the first-line treatment for fibromyalgia 4, 5
The American Psychological Association suggests adding cognitive behavioral therapy, particularly for patients with comorbid depression, anxiety, or maladaptive coping strategies, to improve treatment outcomes 4, 5

The guideline society recommends starting duloxetine 30 mg daily for 1 week, then increasing to 60 mg daily, and reassessing pain levels, function, and side effects every 4-8 weeks, according to the American Academy of Neurology 4, 5
If duloxetine 60 mg provides partial but inadequate relief, the guideline suggests adding pregabalin, starting 75 mg twice daily, increase to 150 mg twice daily within 1 week based on tolerance, to improve pain, function, sleep, and depression 5

The American College of Physicians advises against using gabapentin as first-line therapy for fibromyalgia due to insufficient evidence and lack of FDA approval for this indication 1, 2
The guideline society warns against escalating duloxetine beyond 60 mg daily, as higher doses provide no additional benefit and increase adverse events and discontinuation rates, according to the American Academy of Pain Medicine 4, 5
The Centers for Disease Control and Prevention recommends against prescribing corticosteroids or strong opioids for fibromyalgia, as they lack efficacy and cause significant harm 4, 5